NCT02641067View on ClinicalTrials.gov

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

May 14, 2016

Study Completion Date

May 25, 2016

Conditions
Renal Impairment
Interventions
DRUG

Doravirine

Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02641067 - A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051) | Biotech Hunter | Biotech Hunter